Insider Selling: MediWound (NASDAQ:MDWD) COO Sells $24,245.00 in Stock

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 1,865 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $13.00, for a total value of $24,245.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Shmuel Hess also recently made the following trade(s):

• On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36.

MediWound Price Performance

MediWound stock opened at $12.66 on Monday. The company’s 50-day moving average is $14.16 and its 200-day moving average is $15.62. The firm has a market capitalization of $162.71 million, a PE ratio of -7.03 and a beta of 0.15. MediWound Ltd. has a fifty-two week low of $12.52 and a fifty-two week high of $20.30.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. As a group, analysts expect that MediWound Ltd. will post -2.31 EPS for the current year.

Hedge Funds Weigh In On MediWound

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP acquired a new stake in MediWound in the 4th quarter worth about $26,000. BNP Paribas Financial Markets grew its position in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares in the last quarter. California State Teachers Retirement System grew its position in shares of MediWound by 281.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,486 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $33.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.